Phase 2 Prospective Trial of Retreatment with [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA. Here, FOLH1 is linked to prostate carcinoma.